Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cerus Corp CERS

Healthcare Medical Instruments & Supplies
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.


NDAQ:CERS - Post by User

Cerus Corp
<< Previous
 Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Apr 12, 2024 12:00pm
49 Views
Post# 35985877

Buy Recommendation Issued On CERS By Craig-Hallum

Buy Recommendation Issued On CERS By Craig-Hallum
Just In: $CERS Buy Recommendation Issued On CERS By Craig-Hallum2024-04-12 09:30:05 ET Craig-Hallum analyst issues BUY recommendation for CERS on April 12, 2024 07:19AM ET. CERS was trading at $1.695 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendationsCERS - Buy Recommendation Issued On CERS By Craig-Hallum

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities